Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid Leukemia
Posted by: DrugsNews on: 12 Dec, 2009
Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid Leukemia
Ambit Biosciences Corporation announced the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML). AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor…
Read more about Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid Leukemia
| Indian Pharmacy! Looking for Generic Medications? Quality Drugs at affordable prices! Reliable Indian Pharmacy www.IndianPharmacy.org |
#1 Canadian Pharmacy Online! The Lowest Prices from Canadian Drugstore! Various payments, secure shopping, worldwide shipping! www.CanadianPharmacyLtd.org |
What are the Drugs-Review websites?
The Drugs-Review websites are NOT but will be your number one stop for all the latest news, comment and pharmaceutical industry information.
Related posts:
- Sunesis Completes Enrollment Of Voreloxin REVEAL-1 Trial In Acute Myeloid Leukemia
- Lorus Therapeutics Announces Positive Result in Its Phase II Clinical Study of LOR-2040 in Acute Myeloid Leukemia (AML)
- Sangamo BioSciences Initiates ZFP Therapeutics Clinical Trial
